Skip to main content
SpringerLink
Log in

Economic Evaluation of Pioglitazone Hydrochloride in the Management of Type 2 Diabetes Mellitus in Canada

  • Original Research Article
  • Published:
PharmacoEconomics Aims and scope Submit manuscript

Abstract

Introduction: Recently published clinical trial results have demonstrated that, in patients with type 2 diabetes mellitus, treatment with pioglitazone hydrochloride as a first-line therapy can lead to significant improvements in glycosylated haemoglobin, total cholesterol, high density lipoprotein cholesterol and triglycerides. Given the results of these trials, we assessed the cost effectiveness of the use of pioglitazone as a first-line therapy in Canada.

Methods: A Markov model was used to determine the health outcomes and economic impact for patients with type 2 diabetes, from the perspective of a provincial ministry of health. The model incorporated six complications of diabetes: hypoglycaemia, acutemyocardial infarction, stroke, lower extremity amputation, nephropathy, and retinopathy. Transition probabilities and costs were taken from published literature. Analysis compared treatment strategies with different first-line therapies: pioglitazone, glibenclamide (glyburide), metformin, and diet and exercise.

Results: Compared with other strategies, a pioglitazone-based strategy was estimated to reduce the cumulative incidence of severe clinical events and long-term complications by between 23 and 36% and to increase discounted life expectancy by between 0.13 and 0.35 life-years. The discounted incremental cost per life-year gained of a first-line pioglitazone-based strategy was 54 000 Canadian dollars ($Can) compared with metformin, $Can42 000 compared with glibenclamide and $Can27 000 compared with diet and exercise.

Conclusions: When compared with other currently funded chronic therapy, these results demonstrate that a treatment strategy employing pioglitazone as a first-line therapy may be cost effective for certain patient strata.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Table I
Table II
Table III
Table IV
Table V

Similar content being viewed by others

References

  1. Aronoff S, Rosenblatt S, Braithwaite S, et al. Pioglitazone hydrochloride monotherapy improves glycemic control in the treatment of patients with type 2 diabetes: a 6-month randomized placebo-controlled dose-response study. The Pioglitazone 001 Study Group. Diabetes Care 2000; 23 (11): 1605–11

    Article  PubMed  CAS  Google Scholar 

  2. Pinaire J, Robertson K, Zagar A, et al. Favourable impact of pioglitazone on lipid profile independent of baseline triglyceride in type 2 diabetes mellitus. Presented at the Endocrine Society Meeting; 2001 Jun; Denver (CO)

    Google Scholar 

  3. Einhorn D, Rendell M, Rosenzweig J, et al. Pioglitazone hydrochloride in combination with metformin in the treatment of type 2 diabetes mellitus: a randomized placebo-controlled study. The Pioglitazone 027 Study Group. Clin Ther 2000; 22 (12): 1395–409

    Article  PubMed  CAS  Google Scholar 

  4. Kipnes MS, Krosnick A, Rendell MS, et al. Pioglitazone hydrochloride in combination with sulfonylurea therapy improves glycemic control in patients with type 2 diabetes mellitus: a randomized, placebo-controlled study. Am J Med 2001; 111: 10–7

    Article  PubMed  CAS  Google Scholar 

  5. Anderson RN. United States life tables, 1998. National vital statistics reports; Vol. 48, no. 18. Hyattsville, Maryland: National Center for Health Statistics, 2001

    Google Scholar 

  6. Palmer AJ, Weiss C, Sendi PP, et al. The cost-effectiveness of different management strategies for type I diabetes: a Swiss perspective. Diabetologia 2000; 43: 13–26

    Article  PubMed  CAS  Google Scholar 

  7. Palmer AJ, Sendi PP, Spinas GA. Applying some UK Prospective Diabetes Study results to Switzerland: the cost-effectiveness of intensive glycemic control with metformin versus conventional control in overweight patients with type-2 diabetes. Schweiz Med Wochenschr 2000; 130 (27–28): 1034–40

    PubMed  CAS  Google Scholar 

  8. Rosskamp R. Safety aspects of oral hypoglycaemic agents. Diabetologia 1996; 39: 1668–72

    Article  PubMed  CAS  Google Scholar 

  9. Actos Prescibing Information. Eli Lilly Canada, 2000

  10. Matthews DR, Cull CA, Stratton IM, et al. UKPDS 26: Sulphonylurea failure in non-insulin-dependent diabetic patients over six years. UK Prospective Diabetes Study (UKPDS) Group. Diabet Med 1998; 15 (4): 297–303

    Article  PubMed  CAS  Google Scholar 

  11. Chun B, Coyle D, Berthelot JM, et al. Estimating the cost of coronary heart disease in Manitoba. Proceedings of the American Statistical Association Joint Annual Meeting. 1997 Mar; Chicago (IL)

    Google Scholar 

  12. Smurawsksa LT, Alexandrov AV, Bladin CF. Cost of acute stroke care in Toronto, Canada. Stroke 1994; 25: 1628–31

    Article  Google Scholar 

  13. Rivière M, Wang S, Leclerc C, et al. Cost-effectiveness of simvastatin in the secondary prevention of coronary artery disease in Canada. CMAJ 1997; 156: 991–7

    PubMed  Google Scholar 

  14. Jacobs P, Bachynsky J. An Alberta standard cost list for health economics evaluations. Institute for Pharmacoeconomics, 1997. Working paper: 97–5

    Google Scholar 

  15. Alberta Physician Fee Schedule. Edmonton: Alberta Health and Wellness, 1999

  16. Tan MH, MacLean DR. Epidemiology of diabetes mellitus in Canada. Clin Invest Med 1995; 18 (4): 240–6

    PubMed  CAS  Google Scholar 

  17. Ontario Case Costing Project (OCCP). Toronto: Ontario Ministry of Health, 1999

  18. Johansen K. Efficacy of metformin in the treatment of NIDDM. Meta-analysis. Diabetes Care 1999; 22: 33–7

    Article  PubMed  CAS  Google Scholar 

  19. Hermann LS, Schersten B, Per-Olof B, et al. Therapeutic comparison of metformin and sulphonylurea, alone and in various combinations. Diabetes Care 1994; 17: 1100–9

    Article  PubMed  CAS  Google Scholar 

  20. Laupacis A, Feeny D, Detsky AS, et al. How attractive does a new technology have to be to warrant adoption and utilization. Tentative guidelines for using clinical and economic evaluations. CMAJ 1992; 146 (4): 473–81

    PubMed  CAS  Google Scholar 

  21. Churchill DN, Lemon DC, Torrance GW. Cost-effectiveness analysis comparing continuous ambulatory peritoneal dialysis to hospital hemodialysis. Med Decis Making 1984; 4: 489–500

    Article  Google Scholar 

  22. Goel V, Deber RB, Detsky AS. Nonionic contrast media: economic analysis and health policy development. CMAJ 1989; 140: 389–95

    PubMed  CAS  Google Scholar 

  23. Naylor CD, Baigrie RS, Goldman BS, et al. Assessment of priority for coronary revascularization procedures. Lancet 1990; 335: 1070–3

    Article  PubMed  CAS  Google Scholar 

  24. Oliver A, Pritchard C. Economic evaluations relating to diabetes: a descriptive review and their compliance with guidance. Value Health 2000; 3: s7–14

    Article  Google Scholar 

  25. MacKeigan LD. A short term cost-effectiveness model for oral antidiabetic medicines in Europe. Pharmacoeconomics 1998; 14 (6): 709–10

    Article  PubMed  CAS  Google Scholar 

  26. Hood S, Annemans L, Rutten-van Molken M. A short term cost-effectiveness model for oral antidiabetic medicines in Europe. Pharmacoeconomics 1998; 13 (3): 317–26

    Article  PubMed  CAS  Google Scholar 

  27. Caro JJ, Klittich WS, Raggio G, et al. Economic assessment of troglitazone as an adjunct to sulfonylurea therapy in the treatment of type 2 diabetes. Clin Ther 2000; 22 (1): 116–27

    Article  PubMed  CAS  Google Scholar 

  28. Campbell IW. Epidemiology and clinical presentation of type 2 diabetes. Value Health 2000; 3: s3–6

    Article  Google Scholar 

  29. Holmes J, McGill S, Kind P, et al. Health-related quality of life in type 2 diabetes (T2ARDIS-2). Value Health 2000; 3: s47–51

    Article  Google Scholar 

  30. Eastman RC, Javitt JC, Herman WH, et al. Model of complications of NIDDM. I. Model construction and assumptions. Diabetes Care 1997; 20: 725–34

    Article  PubMed  CAS  Google Scholar 

  31. Brown JB, Russell A, Chan W, et al. The global diabetes model: user friendly version 3.0. Diabetes Res Clin Pract 2000; 50 Suppl. 3: S15–46

    Article  PubMed  Google Scholar 

  32. Brown JB, Palmer AJ, Bisgaard P, et al. The Mt. Hood challenge: cross-testing two diabetes simulation models. Diabetes Res Clin Pract 2000; 50 Suppl. 3: S57–64

    Article  PubMed  Google Scholar 

Download references

Acknowledgements

Funding was provided by Eli Lilly Canada Inc. The principal author had independent control over the contents of the manuscript.

Author information

Authors and Affiliations

  1. Departments of Medicine and Epidemiology, and Community Medicine, University of Ottawa, Ottawa, Ontario, Canada

    Douglas Coyle

  2. Clinical Epidemiology, Ottawa Health Research Institute, Ottawa Hospital, 1053 Carling Avenue, Ottawa, Ontario, K1Y 4E9, Canada

    Douglas Coyle

  3. Institute of Medical Informatics and Biostatistics, Basle, Switzerland

    Andrew J. Palmer

  4. Eli Lilly Canada Inc., Scarborough, Ontario, Canada

    Robert Tam

Authors
  1. Douglas Coyle
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Andrew J. Palmer
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Robert Tam
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Douglas Coyle.

Additional information

At the time this article was prepared, Andrew J. Palmer was an employee of the Institute of Medical Informatics and Biostatistics. His current affiliation is CORE Center for Outcomes Research, Basle, Switzerland.

At the time this article was prepared, Robert Tam was an employee of Eli Lilly Canada Inc. His current affiliation is Byk Canada, Oakville, Ontario, Canada.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Coyle, D., Palmer, A.J. & Tam, R. Economic Evaluation of Pioglitazone Hydrochloride in the Management of Type 2 Diabetes Mellitus in Canada. Pharmacoeconomics 20 (Suppl 1), 31–42 (2002). https://doi.org/10.2165/00019053-200220001-00004

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00019053-200220001-00004

Keywords

Search

Navigation